Putnam Investments’s Atara Biotherapeutics ATRA Stock Holding History

Putnam Investments’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,512	Closed	-$1.5M	–	888
2019 Q1	$1.5M	Sell	1,512 -9,169	-86%	-$8.52M	﹤0.01%	729
2018 Q4	$9.28M	Sell	10,681 -34	-0.3%	-$31.6K	0.02%	335
2018 Q3	$11.1M	Sell	10,715 -1,135	-10%	-$1.11M	0.02%	372
2018 Q2	$10.9M	Sell	11,850 -60	-0.5%	-$64.5K	0.02%	359
2018 Q1	$11.6M	Buy	+11,910	New	+$10.9M	0.03%	344

Other funds holding ATRA

Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Putnam Investments's ATRA Position: Q2 2019 in Review

Putnam Investments sold out of Atara Biotherapeutics (ATRA) in Q2 2019, closing a stake of 1,512 shares — an estimated $1.5M sold.

Putnam Investments first reported a position in ATRA in Q1 2018 and held it in 5 quarters. The position peaked at $11.6M in Q1 2018. 116 funds tracked by Wall St. Rank hold ATRA as of Q2 2019.

Putnam Investments reported no remaining Atara Biotherapeutics position as of Q2 2019 after selling out during the quarter.
Putnam Investments sold 1,512 Atara Biotherapeutics shares in Q2 2019, an estimated $1.5M.
Putnam Investments first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 5 quarters.
Putnam Investments's Atara Biotherapeutics position peaked at $11.6M in Q1 2018.
116 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2019.

Based on Putnam Investments's 13F filing for Q2 2019, filed 14 Aug 2019.